Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GYKI 53405

Known as: GYKI-53405 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
RationaleAlthough emerging number of data supports the role of glutamate receptors and the potential of their antagonists in… Expand
  • figure 1
  • table 2
  • table 1
  • figure 2
  • figure 3
2007
2007
Blockade of AMPA (α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid) receptors is a good treatment option for a variety of… Expand
2007
2007
Although levodopa is the current "gold standard" for treatment of Parkinson's disease, there has been disputation on whether AMPA… Expand
2006
2006
EGIS-8332 and GYKI 53405 are selective, non-competitive AMPA (2-amino-3[3-hydroxy-5-methyl-4-isoxazolyl] propionic acid… Expand
2004
2004
Antagonists of 2-amino-3(3-hydroxy-5-methyl-4-isoxazolyl) propionic acid (AMPA) receptors can considerably reduce brain damage… Expand
2004
2004
The release of [3H]dopamine was measured in rat corticostriatal slice preparations that contained the striatum and the adjacent… Expand
2001
2001
GYKI 52466 [1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine], a non-competitive AMPA [alpha-amino-3-hydroxy-5… Expand
Highly Cited
1996
Highly Cited
1996
1 The 2,3‐benzodiazepines GYKI 52466, GYKI 53405 and GYKI 53655 antagonized AMPA‐induced currents in cultured superior colliculus… Expand